Ceftolozane + Tazobactam for Injection bulk supplier for pharma manufacturers

Ceftolozane + Tazobactam for Injection 1 g + 0.5 g Suppliers & Bulk Manufacturers

Available Forms: Powder for concentrate vial (IV infusion)

Available Strengths: 1 g + 0.5 g

Pack Sizes: Packs of 10 vials

Reference Brands: Zerbaxa (MSD)

Ceftolozane-tazobactam (Zerbaxa, MSD) is a hospital antibiotic with strong activity against multidrug-resistant Pseudomonas aeruginosa, used for complicated urinary and abdominal infections and hospital-acquired pneumonia. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ceftolozane + Tazobactam for Injection? List it or send an offer →

Product Description:

Ceftolozane is a cephalosporin designed to resist the defence mechanisms of Pseudomonas aeruginosa, one of the hardest hospital bacteria to treat. Tazobactam is added to block many extended-spectrum beta-lactamases. Together they often remain active against Pseudomonas strains that are resistant to carbapenems, piperacillin-tazobactam and ceftazidime.

It is approved for complicated urinary tract infections, complicated intra-abdominal infections (with metronidazole) and hospital-acquired or ventilator-associated pneumonia. It is given by intravenous infusion every eight hours; the pneumonia dose is double the standard dose. It does not cover carbapenemase-producing bacteria, so susceptibility testing guides its use.

Sourcing notes. Ceftolozane-tazobactam is protected by patents in major markets and is supplied by the originator. Hospitals in countries where it is not registered can often import it through named-patient or special-access routes. Ceftazidime-avibactam and meropenem-vaborbactam are also listed on PharmaTradz.

How Ceftolozane + Tazobactam for Injection is supplied today, and licensing ahead of patent expiry

Ceftolozane + Tazobactam for Injection is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Ceftolozane + Tazobactam for Injection, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Ceftolozane + Tazobactam for Injection supply →

Back to Listing